Free Newsletter
Synthetic compound works as targeted cancer therapy
A synthetic compound developed in the lab at UT Southwestern Medical Center mimics the cellular protein Smac, broadcasting a message to cancer cells that triggers their destruction. In a study published in Cancer Cell, the researchers--led by Dr. Xiaodong Wang--found that the compound induced cell death in about one quarter of all the lung-cancer lines tested while demonstrating activity against some types of breast cancer. Wang says the scientific team found that the cell lines that were sensitive to the action of synthetic Smac produced tumor necrosis factor-a (TNFa), which by itself promotes the development of cancer. Combined with the compound, though, the cells die.
"The apparent ability of a Smac mimetic, as a single agent, to induce cell death in nearly one-quarter of lung-cancer cell lines tested was quite remarkable," said Dr. Wang, who is a Howard Hughes Medical Institute investigator at UT Southwestern.
- check out the release
- read the UPI report on the compound
Related Articles:
Synthetic biology spawns fresh approach to antibiotics. Report
Scripps team finds path to synthesizing natural compounds. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: